Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia

David J. Kuter, Barbara A. Konkle, Taye H. Hamza, Lynne Uhl, Susan F. Assmann, Joseph E. Kiss, Richard M. Kaufman, Nigel S. Key, Bruce S. Sachais, John R. Hess, Paul Ness, Keith R. McCrae, Cindy Leissinger, Ronald G. Strauss, Janice G. McFarland, Ellis Neufeld, James B. Bussel, Thomas L. Ortel

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background: Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder usually prompting treatment with non-heparin anticoagulants. The benefits and risks of such treatments have not been fully assessed. Methods: We analyzed data for 442 patients having a positive heparin-platelet factor 4 antibody test and recent heparin exposure. The primary outcome was a composite endpoint (death, limb amputation/gangrene, or new thrombosis). Secondary outcomes included bleeding and the effect of anticoagulation. Findings: Seventy-one patients (16%) had HIT with thrombosis (HIT-T); 284 (64%) had HIT without thrombosis (isolated HIT); 87 (20%) did not have HIT. An intermediate or high “4T” score was found in 85%, 58%, and 8% of the three respective groups. Non-heparin anticoagulation was begun in 80%, 56%, and 45%. The composite endpoint occurred in 48%, 36%, and 17% (P =.01) of which 61%, 38%, and 40% were receiving non-heparin anticoagulation. Compared with the no HIT group, the composite endpoint was significantly more likely in HIT-T [HR 2.48 (1.35-4.55), P =.003)] and marginally more likely in isolated HIT [HR 1.66 (0.96-2.85), P =.071]. Importantly, risk increased (HR 1.77, P =.02) after platelet transfusion. Major bleeding occurred in 48%, 36%, and 16% of the three groups (P =.005). Non-heparin anticoagulation was not associated with a reduction in composite endpoint events in either HIT group. Interpretation: HIT patients have high risks of death, limb amputation/gangrene, thrombosis, and bleeding. Non-heparin anticoagulant treatment may not benefit all patients and should be considered only after careful assessment of the relative risks of thrombosis and bleeding in individual patients.

Original languageEnglish (US)
Pages (from-to)730-738
Number of pages9
JournalAmerican journal of hematology
Issue number8
StatePublished - Aug 2017

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this